TISIDB

Summary
Symbol	GLB1
Name	galactosidase, beta 1
Aliases	ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location	3p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Lysosome ; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm, perinuclear region Note=Localized to the perinuclear area of the cytoplasm but not to lysosomes.
Domain	PF13364 Beta-galactosidase jelly roll domain PF01301 Glycosyl hydrolases family 35
Function	Isoform 1: Cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans. ; FUNCTION: Isoform 2: Has no beta-galactosidase catalytic activity, but plays functional roles in the formation of extracellular elastic fibers (elastogenesis) and in the development of connective tissue. Seems to be identical to the elastin-binding protein (EBP), a major component of the non-integrin cell surface receptor expressed on fibroblasts, smooth muscle cells, chondroblasts, leukocytes, and certain cancer cell types. In elastin producing cells, associates with tropoelastin intracellularly and functions as a recycling molecular chaperone which facilitates the secretions of tropoelastin and its assembly into elastic fibers.

> Gene Ontology [ TOP ]
Biological Process	GO:0005996 monosaccharide metabolic process GO:0006012 galactose metabolic process GO:0006022 aminoglycan metabolic process GO:0006026 aminoglycan catabolic process GO:0006027 glycosaminoglycan catabolic process GO:0006643 membrane lipid metabolic process GO:0006664 glycolipid metabolic process GO:0006665 sphingolipid metabolic process GO:0006687 glycosphingolipid metabolic process GO:0006790 sulfur compound metabolic process GO:0016052 carbohydrate catabolic process GO:0019318 hexose metabolic process GO:0019320 hexose catabolic process GO:0019388 galactose catabolic process GO:0030203 glycosaminoglycan metabolic process GO:0042339 keratan sulfate metabolic process GO:0042340 keratan sulfate catabolic process GO:0044262 cellular carbohydrate metabolic process GO:0044273 sulfur compound catabolic process GO:0044282 small molecule catabolic process GO:0044723 single-organism carbohydrate metabolic process GO:0044724 single-organism carbohydrate catabolic process GO:0046365 monosaccharide catabolic process GO:1901136 carbohydrate derivative catabolic process GO:1901565 organonitrogen compound catabolic process GO:1903509 liposaccharide metabolic process GO:1903510 mucopolysaccharide metabolic process
Molecular Function	GO:0004308 exo-alpha-sialidase activity GO:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds GO:0004565 beta-galactosidase activity GO:0015925 galactosidase activity GO:0016798 hydrolase activity, acting on glycosyl bonds GO:0016936 galactoside binding GO:0016997 alpha-sialidase activity
Cellular Component	GO:0005775 vacuolar lumen GO:0043202 lysosomal lumen

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04142 Lysosome hsa00052 Galactose metabolism hsa00511 Other glycan degradation hsa00531 Glycosaminoglycan degradation hsa00600 Sphingolipid metabolism hsa00604 Glycosphingolipid biosynthesis - ganglio series hsa01100 Metabolic pathways
Reactome	R-HSA-446203: Asparagine N-linked glycosylation R-HSA-446193: Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein R-HSA-1630316: Glycosaminoglycan metabolism R-HSA-1660662: Glycosphingolipid metabolism R-HSA-2024096: HS-GAG degradation R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-2022857: Keratan sulfate degradation R-HSA-1638074: Keratan sulfate/keratin metabolism R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-392499: Metabolism of proteins R-HSA-6798695: Neutrophil degranulation R-HSA-597592: Post-translational protein modification R-HSA-4085001: Sialic acid metabolism R-HSA-428157: Sphingolipid metabolism R-HSA-446219: Synthesis of substrates in N-glycan biosythesis

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04142 Lysosome
hsa00052 Galactose metabolism
hsa00511 Other glycan degradation
hsa00531 Glycosaminoglycan degradation
hsa00600 Sphingolipid metabolism
hsa00604 Glycosphingolipid biosynthesis - ganglio series
hsa01100 Metabolic pathways

Reactome

R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-446193: Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-1660662: Glycosphingolipid metabolism
R-HSA-2024096: HS-GAG degradation
R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-2022857: Keratan sulfate degradation
R-HSA-1638074: Keratan sulfate/keratin metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-597592: Post-translational protein modification
R-HSA-4085001: Sialic acid metabolism
R-HSA-428157: Sphingolipid metabolism
R-HSA-446219: Synthesis of substrates in N-glycan biosythesis

Summary
Symbol	GLB1
Name	galactosidase, beta 1
Aliases	ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location	3p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between GLB1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between GLB1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29653690	colon carcinoma	Promote immunity	We used a pCMV-LacZ plasmid (expressing β-galactosidase) and a pcDNA-hNIS plasmid (expressing the human sodium/iodide symporter [hNIS] gene) as non-secreted visual-imaging markers.

Summary
Symbol	GLB1
Name	galactosidase, beta 1
Aliases	ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location	3p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of GLB1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	GLB1
Name	galactosidase, beta 1
Aliases	ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location	3p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of GLB1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.198	0.461
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.436	0.844
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.02	0.991
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.191	0.497
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.024	0.992
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.405	0.896
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.098	0.816
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.013	0.994
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.276	0.891
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.126	0.941
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.561	0.825
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.084	0.251

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of GLB1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	11.1	8.9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	GLB1
Name	galactosidase, beta 1
Aliases	ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location	3p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GLB1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	GLB1
Name	galactosidase, beta 1
Aliases	ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location	3p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GLB1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GLB1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	GLB1
Name	galactosidase, beta 1
Aliases	ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location	3p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GLB1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	GLB1
Name	galactosidase, beta 1
Aliases	ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location	3p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of GLB1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	GLB1
Name	galactosidase, beta 1
Aliases	ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location	3p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between GLB1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	GLB1
Name	galactosidase, beta 1
Aliases	ELNR1; elastin receptor 1, 67kDa; elastin receptor 1 (67kD); MPS4B; acid beta-galactosidase; Elastin recepto ......
Chromosomal Location	3p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting GLB1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse GLB1